<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 13 Apr 2021 07:25:02 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>创新单抗药物申报临床试验病毒安全性相关监管指南调研与技术考量</title><link>https://mp.weixin.qq.com/s/LPB8YEuJQTLMoGyRnnqGvg</link><description></description><content:encoded><![CDATA[创新单抗药物申报临床试验病毒安全性相关监管指南调研与技术考量]]></content:encoded><pubDate>Tue, 13 Apr 2021 06:33:38 +0800</pubDate></item><item><title>原料药中杂质分析技巧</title><link>https://mp.weixin.qq.com/s/QZ_NnjLxuEqxHZ3lSXyY8A</link><description></description><content:encoded><![CDATA[原料药中杂质分析技巧]]></content:encoded><pubDate>Tue, 13 Apr 2021 06:33:38 +0800</pubDate></item><item><title>2021年CAR-T行业研究报告</title><link>https://mp.weixin.qq.com/s/QhjZX3tLTN_dNnYaMjuI7Q</link><description></description><content:encoded><![CDATA[2021年CAR-T行业研究报告]]></content:encoded><pubDate>Tue, 13 Apr 2021 06:33:38 +0800</pubDate></item><item><title>非小细胞肺癌罕见靶点靶向治疗最新研究进展</title><link>https://mp.weixin.qq.com/s/YoPktf2hWF58DgLSGmvA5w</link><description></description><content:encoded><![CDATA[非小细胞肺癌罕见靶点靶向治疗最新研究进展]]></content:encoded><pubDate>Mon, 12 Apr 2021 07:15:55 +0800</pubDate></item><item><title>药物制剂工艺研究和工艺验证</title><link>https://mp.weixin.qq.com/s/V0YdHphEBpyMbbGgN1neJQ</link><description></description><content:encoded><![CDATA[药物制剂工艺研究和工艺验证]]></content:encoded><pubDate>Mon, 12 Apr 2021 07:15:55 +0800</pubDate></item><item><title>药物的多晶型与药物制剂的开发</title><link>https://mp.weixin.qq.com/s/_Cr4xAjLAUZlbfFpW5F5lA</link><description></description><content:encoded><![CDATA[药物的多晶型与药物制剂的开发]]></content:encoded><pubDate>Mon, 12 Apr 2021 07:15:55 +0800</pubDate></item><item><title>替雷利珠单抗注射液 申请上市技术审评报告</title><link>https://mp.weixin.qq.com/s/Yd3-3pB9H8rZmap28z7Tzw</link><description></description><content:encoded><![CDATA[替雷利珠单抗注射液 申请上市技术审评报告]]></content:encoded><pubDate>Sat, 10 Apr 2021 20:40:17 +0800</pubDate></item><item><title>图说：看干细胞如何保护人体八大系统</title><link>https://mp.weixin.qq.com/s/5y5zCkQDkr3YZldJv37Xhg</link><description></description><content:encoded><![CDATA[图说：看干细胞如何保护人体八大系统]]></content:encoded><pubDate>Sat, 10 Apr 2021 20:40:17 +0800</pubDate></item><item><title>生物药研发注册申报及质量研究</title><link>https://mp.weixin.qq.com/s/c4kvc6FFJkjJXP3AsCXkEA</link><description></description><content:encoded><![CDATA[生物药研发注册申报及质量研究]]></content:encoded><pubDate>Sat, 10 Apr 2021 20:40:17 +0800</pubDate></item><item><title>乳腺癌靶向药物的研究及临床应用新进展</title><link>https://mp.weixin.qq.com/s/jrVzkltbPIdIqF6kOFQf2A</link><description></description><content:encoded><![CDATA[乳腺癌靶向药物的研究及临床应用新进展]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:10:56 +0800</pubDate></item><item><title>CDK4/6靶向药：七大问题，范蕾教授为您一次解答！</title><link>https://mp.weixin.qq.com/s/x6oTk2Jbfxd-JyjW8zid0w</link><description></description><content:encoded><![CDATA[CDK4/6靶向药：七大问题，范蕾教授为您一次解答！]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:10:56 +0800</pubDate></item><item><title>图解｜一图读懂《化妆品分类规则和分类目录》</title><link>https://mp.weixin.qq.com/s/L1d26urhY1EkDl3sOdWUPA</link><description></description><content:encoded><![CDATA[图解｜一图读懂《化妆品分类规则和分类目录》]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:10:56 +0800</pubDate></item><item><title>CAR-T新药跑步上市，国内研发竞赛如火如荼</title><link>https://mp.weixin.qq.com/s/l-XT9zjm739GSIXUlJ7AzQ</link><description></description><content:encoded><![CDATA[CAR-T新药跑步上市，国内研发竞赛如火如荼]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:10:56 +0800</pubDate></item><item><title>2021年中国mRNA治疗行业研究报告</title><link>https://mp.weixin.qq.com/s/F8Hms_HlCwNbklqdou6-6g</link><description></description><content:encoded><![CDATA[2021年中国mRNA治疗行业研究报告]]></content:encoded><pubDate>Thu, 08 Apr 2021 22:21:00 +0800</pubDate></item><item><title>药物研发中如何确定创新药及仿制药杂质限度</title><link>https://mp.weixin.qq.com/s/bjRbXSDcKva91Z2eXeH6XA</link><description></description><content:encoded><![CDATA[药物研发中如何确定创新药及仿制药杂质限度]]></content:encoded><pubDate>Thu, 08 Apr 2021 22:21:00 +0800</pubDate></item><item><title>特异靶向KRAS-G12C突变的抗肿瘤药物研究进展</title><link>https://mp.weixin.qq.com/s/oEl-YptuZfmQ--Ey-K_r_Q</link><description></description><content:encoded><![CDATA[特异靶向KRAS-G12C突变的抗肿瘤药物研究进展]]></content:encoded><pubDate>Thu, 08 Apr 2021 22:21:00 +0800</pubDate></item><item><title>基因治疗制品申报IND/NDA药学评价要点</title><link>https://mp.weixin.qq.com/s/yJZ5YBPw189A75p5-X-4Nw</link><description></description><content:encoded><![CDATA[基因治疗制品申报IND/NDA药学评价要点]]></content:encoded><pubDate>Wed, 07 Apr 2021 20:31:22 +0800</pubDate></item><item><title>药物是怎样从研发到上市的？</title><link>https://mp.weixin.qq.com/s/dP-_iM106ZISuXq0k8_FpQ</link><description></description><content:encoded><![CDATA[药物是怎样从研发到上市的？]]></content:encoded><pubDate>Wed, 07 Apr 2021 20:31:22 +0800</pubDate></item><item><title>研发过程数据可靠性的管理与思考</title><link>https://mp.weixin.qq.com/s/9cr32G68XBg4bp9Gs5BS8w</link><description></description><content:encoded><![CDATA[研发过程数据可靠性的管理与思考]]></content:encoded><pubDate>Wed, 07 Apr 2021 20:31:22 +0800</pubDate></item><item><title>阿达木单抗注射液申请上市技术审评报告</title><link>https://mp.weixin.qq.com/s/SJIR3LjdD9zgS5B8ck5CPw</link><description></description><content:encoded><![CDATA[阿达木单抗注射液申请上市技术审评报告]]></content:encoded><pubDate>Tue, 06 Apr 2021 22:16:44 +0800</pubDate></item></channel></rss>